Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aniracetam SCHEMBL9797179 | 1.00 | KMT2A (1.00) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| Aniracetam SCHEMBL15015927 | 0.94 | MAPT (0.89) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL26947628 | 0.87 | MEN1 (0.77) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL5182886 | 0.87 | KMT2A (0.75) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| Aniracetam SCHEMBL6384696 | 0.86 | KMT2A (0.74) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL10523544 | 0.84 | KMT2A (0.72) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL31472651 | 0.83 | MAPT (0.71) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL8377415 | 0.81 | MITF (0.73) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL8985531 | 0.81 | MAPT (0.68) | KMT2AKDM4EMEN1CYP1A2CYP2D6 | |
| SCHEMBL11179889 | 0.80 | KMT2A (0.67) | KMT2AKDM4EMEN1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3483 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746864-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION | Keto Innovations, LLC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4744670-A1 | POLYLACTIC ACID AND USE OF COPOLYMER THEREOF IN PREPARATION OF DRUG FOR PROMOTING NERVE GROWTH AND REPAIR | Changchun Sinobiomaterials Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090582-A1 | COMPOSITIONS CONTAINING A NON-XANTHINE CNS STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4712954-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | Keto Innovations, LLC (US) | 2026-03-25 | — | — | EP | claimed |
| CN-120152491-A | Perovskite battery modified based on pyrrolidone derivative and preparation method thereof | 敬硕科技(河北)有限责任公司 | 2025-06-13 | — | — | CN | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| CN-119564814-A | Composition for preventing senile dementia and preparation method thereof | 山东省青州荣军医院 | 2025-03-07 | — | — | CN | claimed |
| US-20250049805-A1 | COMPOSITIONS CONTAINING A NON-CAFFEINE STIMULANT OR NOOTROPIC AND BETA-HYDROXYBUTYRATE OR PRECURSOR FOR INCREASING NEUROLOGICAL AND PHYSIOLOGICAL PERFORMANCE | AXCESS GLOBAL SCIENCES, LLC | 2025-02-13 | — | — | US | claimed |
| CN-118986864-B | Electroactive multifunctional hydrogel and preparation method and application thereof | 四川大学 | 2025-02-07 | — | — | CN | claimed |
| WO-2025026457-A1 | MODIFIED FLAVONE COMPOUNDS AND USE THEREOF | 苏州格兰科医药科技有限公司 | 2025-02-06 | — | — | WO | claimed |
| EP-0243336-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INTERMITTENT CLAUDICATION | U C B, S.A. (BE) | 1990-06-13 | — | — | EP | claimed |
| US-4876260-A | NERVOUS SYSTEM DISORDERS | STATE OF ISRAEL, ISRAEL INSTITUTE OF BIOLOGICAL RESEARCH (IL) | 1989-10-24 | — | — | US | claimed |
| US-4855290-A | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1989-08-08 | — | — | US | claimed |
| EP-0314444-A2 | Novel oxathiolanes and derivatives thereof, pharmaceutical compositions containing them and the use thereof as medicaments | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-05-03 | — | — | EP | claimed |
| EP-0303391-A2 | Optical isomers of a spiroquinuclidine derivative | State of IsraelRepresented by the Prime Minister's OfficeThe Israel Institute for Biological Research (IL) | 1989-02-15 | — | — | EP | claimed |
| EP-0205247-A2 | Derivatives of quinuclidine | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1986-12-17 | — | — | EP | claimed |
| EP-0116238-A1 | Therapeutic compositions and their use in enhancing brain function | BIOMEASURE, INC. (US) | 1984-08-22 | — | — | EP | claimed |
| US-4369139-A | PREVENTION OF CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0005143-B1 | 1-BENZOYL-2-PYRROLIDINONE DERIVATIVE, PROCESSES FOR ITS PREPARATION AND MEDICAMENTS CONTAINING IT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-07-14 | — | — | EP | claimed |
| EP-0005143-A1 | 1-Benzoyl-2-pyrrolidinone derivative, processes for its preparation and medicaments containing it | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-11-14 | — | — | EP | claimed |